EICHORCondition: Mantle Cell Lymphoma (MCL) · Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD.
This is an open-label, single arm, multi-center Phase 2 study of oral Rocbrutinib in patients with mantle cell lymphoma who are failed or relapsed after remission or intolerated to Bruton's tyrosine kinase (BTK) inhibitor.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Anhui provincial cancer hospital | Hefei, Anhui, China | — |
| The first affiliated hospital of Anhui medical university | Hefei, Anhui, China | — |
| Peking University Third Hospital | Beijing, Beijing Municipality, China | — |
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | — |
| The first affiliated hospital of Chongqing mediacal university | Chongqing, Chongqing Municipality, China | — |
| Fujian Cancer Hospital | Fuzhou, Fujian, China | — |
| Fujian Medical university union hospital | Fuzhou, Fujian, China | — |
| The first affiliated hospital of Xiamen university | Xiamen, Fujian, China | — |
| Gansu provincial cancer hospital | Lanzhou, Gansu, China | — |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | — |
| Meizhou people'shospital | Meizhou, Guangdong, China | — |
| The First Affiliated Hospital of Guangxi Medical University | Nanning, Guangxi, China | — |
+ 31 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05716087